In the LIBERTY-AFRS-AIMS trial, 62 adults and children aged 6 years and older with AFRS were randomized to receive an age- and weight-based dose of Dupixent (200 mg or 300 mg; n=33) every two or four ...
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) reported positive data from the late-stage trial, which assessed Dupixent ...
TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® ...
New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair ...
The approval in adolescent patients was based on evidence from the phase 3 SINUS-24 and SINUS-52 trials. The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® (dupilumab) to ...
Please provide your email address to receive an email when new articles are posted on . EVEREST represents the first head-to-head study of these biologics for CRSwNP. Differences between the biologics ...
Confirmatory data to support U.S. regulatory resubmission by year-end; if approved, Dupixent would be the first new targeted treatment for people living with chronic spontaneous urticaria in more than ...
Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic ...
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback